DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Chemotherapy regimen
Chemotherapy regimen
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
THE STRUCTURED STORAGE of ONCOLOGICAL CHEMOTERAPEUTIC REGIMENS Contribution to Standardization of Therapeutic Procedures in Current Oncology
A Phase II Trial of the Src-Kinase Inhibitor AZD0530 in Patients with Advanced Castration-Resistant Prostate Cancer: a California Cancer Consortium Study Primo N
Is Combined Chemotherapy with Cisplatin, Etoposide and Irinotecan the New Standard Treatment for Patients with Sensitive Relapsed Small Cell Lung Cancer?
Taxotere (Docetaxel) Label
Advances in Cancer Research Hariharan U*
DEXAMETHASONE – RITUXIMAB (DRC) Regimen • Lymphoma
Chemotherapy Regimens for Lymphoma
Thames Valley Chemotherapy Regimens Lung Cancer
AC 60/600) 14 Day Followed by Paclitaxel (175) 14 Day Therapy (DD AC-T
Diffuse Large B-Cell Lymphoma (Part 1 of 5)
The Cancer and Leukemia Group B Lymphoma Committee Bruce D
Weekly Chemotherapy with Cisplatin and Paclitaxel in Inoperable Non-Small Cell Lung Cancer: an Extended Phase II Study*
Outpatient Oral Anticancer Agents in Manitoba
The Chemotherapy of Lymphomas: Looking Back, Moving Forward—The Richard and Hinda Rosenthal Foundation Award Lecture1
ETOPOSIDE 1. Exposure Data
79. Mitosis Inhibitors Mitosis Is the Process in Which a Eukaryotic Cell Separates the Chromosomes in Its Cell Nucleus Into Two Identical Sets in Two Daughter Nuclei
CHMP Assessment Report
Top View
Clinical Development of Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin Lymphoma Xiaosheng Fang1, Xiangxiang Zhou1 and Xin Wang1,2*
Targeting the PI3K/AKT Pathway for the Treatment of Gastric Cancer
Chemotherapy Regimen: TC
(Neo)Adjuvant Trastuzumab for HER2-Positive Early
Chemotherapy: Drugs P-Z Policy (Chemo Drug P-Z)
A Kinase Inhibitor with Anti-Pim Kinase Activity Is a Potent And
Mechanism Studies of Antitubulin Agents-Mediated MMP Down-Regulation and Nitroxoline Repurposing in Human Prostate Cancer Cells
Paclitaxel Monotherapy 80Mg/M2 Day 1, 8, 15 and 22 – 28 Day
Chemotherapy
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Methotrexate Injection, USP Rx Only
CNS Lymphoma Regimen
Primary CNS Lymphoma)
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives
Oncology Agents Policy #: Rx.01.67
Important Drug Information
Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia
Treatment Patterns and Survival in HER2-Positive Early Breast Cancer: a Whole-Of-Population Australian Cohort Study (2007–2016)
Carboplatin and Vincristine Chemotherapy for Children with Newly Diagnosed Progressive Low-Grade Gliomas
Chemotherapy Regimen
Hodgkin Lymphoma: Faculty Advancing Beyond Standard Volker Diehl, MD Professor of Medicine University of Cologne Management Cologne, Germany
Anti-Cancer Drugs As Part of Chemotherapy Regimen
Chemotherapy Regimen
Ifosfamide/Etoposide Alternating with High-Dose Methotrexate (IEM) Related to Primary Treatment Details in Relapsed, Evaluable Patients
Systemic Therapy: Chemotherapy for Breast Cancer
Phosphatidylinositol 3-Kinase (Pi3k) As a Therapeutic Target in Nsclc
Oral Chemotherapy– What Your Patients Need to Know
Chemotherapy Regimen: ESHAP
No. Reference Year Country Denominator
1 Mtorc1 Inhibition Induces Resistance To
Low-Cost Outpatient Chemotherapy Regimen of Cisplatin, 5-Fluorouracil
Ddac-T Chemotherapy Teaching
AIM (Doxorubicin + Ifosfamide +
PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE
Selection of Optimal Adjuvant Chemotherapy And
Topoisomerase IIA Expression As an Independent Prognostic Factor In
Correlation Between the Efficacy of Amrubicin and the Previous Chemotherapy Regimen for Relapsed Small Cell Lung Cancer
Tyrosine Kinase Receptors in Oncology